Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 716

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 716
---
 or greater, were not considered to be material for each respective period. Based on the Company’s review of these securities, the Company believes that the cost basis of its available-for-sale marketable security is recoverable.

U.S. government agency obligations.The unrealized loss on the Company’s investment in direct obligations of U.S.governmentagencies were due to changes in interest rates and non-credit related factors. The credit ratings of this investment in the Company’s portfolio have not been downgraded below investment grade status. The contractual terms of this investment do not permit the issuer to repay principal at a price less than the amortized cost bases of the investment, which is equivalent to the par value on the maturity date. The Company expects to recover the entire amortized cost basis of this security on the maturity date. The Company does not intend to sell this investment, and it is not “more likely than not” that the Company will be required to sell this investment before recovery of the amortized cost basis. The Company heldoneposition for its U.S. government agency obligations that were in unrealized loss position as of September 30, 2024.

F- 12

CARA THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (amounts in thousands, except share and per share data) (unaudited)

The Company classifies its marketable debt securities based on their contractual maturity dates. As of September 30, 2024, the Company’s marketable debt security matures in November 2024. The amortized cost and fair values of marketable debt securities by contractual maturity were as follows:

| ​                    | ​ 
 ​ | ​              
 ​              |                        ​ 
 As of September 30, 2024 | ​ | ​          |     ​ | ​ | ​              
 ​              |                       ​ 
 As of December 31, 2023 | ​ | ​          |      ​ |
|:---------------------|:--|:---------------|-------------------------:|:--|:-----------|------:|:--|:---------------|------------------------:|:--|:-----------|-------:|
| Contractual maturity |   | Amortized Cost |                          |   | Fair Value |       |   | Amortized Cost |                         |   | Fair Value |        |
| Less than one year   | ​ | $              |                    5,000 | ​ | $          | 4,975 | ​ | $              |                  49